Want to see SNOA full AI Analyst Report?
SNOA Stock Chart & Stats
$1.14
<$0.01(0.88%)
At close: 4:00 PM EDT
$1.14
<$0.01(0.88%)
Day’s Range― - ―
52-Week Range$0.85 - $5.18
Previous Close$1.2
Volume25.25K
Average Volume (3M)65.28K
Market Cap
$6.42M
Enterprise Value$0.13
Total Cash (Recent Filing)$5.34M
Total Debt (Recent Filing)$739.00K
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding4,788,425
10 Day Avg. Volume126,678
30 Day Avg. Volume65,281
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.16
Price to Sales (P/S)0.18
P/FCF Ratio-0.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$23.91M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Stable Gross MarginRevenue expansion alongside a steady gross margin indicates continued product demand and reasonably durable unit economics. If maintained, this growth can improve operating leverage as the company scales its commercialization base.
Manageable Leverage And Capital CushionRelatively low leverage reduces near-term solvency pressure and preserves financial flexibility compared with a highly debt-funded model. The asset and equity base provides some cushion while management works toward sustainable profitability.
Microcyn Platform And Diversified CommercializationA platform spanning wound care, dermatology and infection control supports multiple healthcare use cases, while direct and partner-led channels broaden market access. Chronic wound and skin-care applications may also support repeat purchasing.
Bears Say
Persistent Operating And Net LossesThe company has not yet covered its operating cost base, so revenue growth has not translated into profitability. Continued losses could constrain reinvestment, weaken equity value over time and increase reliance on external financing.
Negative And Worsening Cash GenerationOngoing cash consumption means the business is not self-funding, while the deterioration in free cash flow raises execution risk. Persistent burn could force additional capital raising before operating improvements become sufficient.
Equity Financing And Shareholder Dilution RiskExpanded access to equity capital can fund operations, but repeated share issuance may dilute existing holders and signal that internal cash generation remains inadequate. This can limit strategic flexibility until profitability improves.
Sonoma Pharmaceuticals News
SNOA FAQ
What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $0.85 and its highest was $5.18 in the past 12 months.
What is Sonoma Pharmaceuticals’s market cap?
Sonoma Pharmaceuticals’s market cap is $6.42M.
When is Sonoma Pharmaceuticals’s upcoming earnings report date?
Sonoma Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.
How were Sonoma Pharmaceuticals’s earnings last quarter?
Sonoma Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported $0.015 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sonoma Pharmaceuticals overvalued?
According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued.
Does Sonoma Pharmaceuticals pay dividends?
Sonoma Pharmaceuticals does not currently pay dividends.
What is Sonoma Pharmaceuticals’s EPS estimate?
Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals has 4,788,425 shares outstanding.
What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
Sonoma Pharmaceuticals reported an EPS of $0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.619%.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
Currently, no hedge funds are holding shares in SNOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Technical Analysis
Perrigo Company
―
Organogenesis Holdings
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
7.38%
Insiders
0.70% Mutual Funds
0.23% Other Institutional Investors
91.29% Public Companies and
Individual Investors